Revelation Biosciences Inc
Research Revelation Biosciences Inc (REVB) on Bullrun: market cap USD 3.91M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerREVB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.91M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 3.32M
- Free cash flow-USD 2.60M
Valuation Snapshot
latest market cap is USD 3.91M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 8.91M | -USD 8.27M | n/a | -23.95 | USD 10.70M | USD 746.78K | USD 8.86M |
| FY2024 | USD 0 | -USD 15.04M | -USD 18.34M | n/a | -1052.16 | USD 6.50M | USD 0 | USD 4.71M |
| FY2023 | n/a | -USD 120.25K | -USD 7.29M | n/a | -8.44 | USD 11.99M | n/a | USD 6.65M |
| FY2022 | n/a | -USD 10.83M | n/a | n/a | -149.2 | USD 5.25M | USD 0 | USD 1.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.91M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.07M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.85M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.17M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.83M | n/a | n/a | n/a |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Revelation Biosciences Inc's market cap?
Revelation Biosciences Inc's market capitalization is USD 3.91M.
What does Revelation Biosciences Inc do?
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response.